Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received RYBELSUS than placebo: RYBELSUS 14 mg once daily (41%), RYBELSUS 7 mg once daily (32%) and placebo (21%), including severe reactions (RYBELSUS 14 mg 2.0%, RYBELSUS 7 mg 0.6%, placebo 0.3%)
Nausea was more frequent with tirzepatide vs placebo, especially with tirzepatide 15 mg (OR 5.60 [95% CI 3.12, 10.06]), associated with higher incidence of vomiting (OR 5.50 [95% CI 2.40, 12.59]) and diarrhoea (OR 3.31 [95% CI 1.40, 7.85])
Production has ramped up and the FDA has ordered compounding pharmacies to stop making the drugs
And thats something that throughout human evolution was ingrained, right
If such a combination is considered necessary, a baseline ECG and assessment of electrolytes should be discussed with the prescribing clinician
Additional factors such as cost and insurance coverage may also play a role in the choice between oral semaglutide versus injectable forms
